There may be a “promising new strategy” in combating aggressive forms of prostate cancer, according to a new study. Researchers at Flinders University and the University of South Australia investigated how the novel drug, CDKI-73, has the potential to tackle drug-resistant prostate cancer. This drug reportedly “defies conventional therapies,” as noted in the study findings,...
A drug called ribociclib, currently used to treat breast cancer, could slow the progression of certain pediatric high-grade gliomas, an aggressive type of childhood brain cancer, a new study has found. Ribociclib (brand name Kisqali) is a CDK4/6 inhibitor, a type of drug that targets specific enzymes — including the protein CDK6 — to stop...
President Joe Biden, alongside first lady Jill Biden, delivered remarks Tuesday in New Orleans addressing his revamped “Cancer Moonshot” program, which seeks to cut the cancer death rate in the U.S. by about half over the next 25 years. During the president’s remarks, which took place at Tulane University, he focused on the need to...
The prevalence of cancer among men is expected to skyrocket globally in the coming decades, according to a new study from the American Cancer Society (ACS). To predict future risk, Australian researchers analyzed the mortality rates tied to 30 different types of cancer among adult men in 2022, based on data from the International Agency...
The U.S. Food and Drug Administration (FDA) has approved a new drug for certain adult patients with endometrial cancer. Jemperli (dostarlimab-gxly) — made by British pharmaceutical company GSK — is intended for people with primary advanced or recurrent forms of the cancer, according to the FDA’s Aug. 1 announcement. It is an immunotherapy-based drug, which...
Certain types of cancers are more prevalent among Gen X and millennials, according to a new study led by the American Cancer Society (ACS). The study, published in the journal The Lancet Public Health, analyzed data from over 23 million patients who were diagnosed with 34 different types of cancer over two decades. The patients...
Screening for the second leading cause of cancer deaths just got a bit easier. The U.S. Food and Drug Administration (FDA) announced the approval of a new blood test for colorectal cancer (CRC). Shield, made by Guardant Health in California, is the first approved blood test that is considered a primary screening option for the...
Artificial intelligence is outpacing doctors when it comes to detecting a common cancer in men. A new study from UCLA found that an AI tool identified prostate cancer with 84% accuracy — compared to 67% accuracy for cases detected by physicians, according to a press release from the university. Unfold AI, made by Avenda Health...
A chemotherapy drug could cause “significant” hearing loss among cancer survivors, according to a study from the University of South Florida and Indiana University. Researchers tracked 100 testicular cancer survivors who received a chemo drug called cisplatin for an average of 14 years, as a press release from USF noted. Among the participants, who averaged...
As many as 40% of cancer cases — and up to half of cancer-related deaths — could have been prevented. That’s according to a new study from the American Cancer Society (ACS), which measured the impact of modifiable risk factors for 30 types of cancers among adults over age 30. Some of those factors were...
